US10898494 — Dry powder treprostinil for the treatment of pulmonary hypertension
Method of Use · Assigned to Liquidia Technologies Inc · Expires 2037-05-05 · 11y remaining
What this patent protects
This patent protects a dry powder inhalation treatment for pulmonary arterial hypertension that includes a capsule with at least 25 micrograms of treprostinil.
USPTO Abstract
A dry powder inhalation treatment for pulmonary arterial hypertension includes a dose of dry particles comprising greater than 25 micrograms of treprostinil enclosed in a capsule. The dry particles can include treprostinil, a wetting agent, a hydrophobicity modifying agent, a pH modifying agent and a buffer. A method of treating a patient having pulmonary arterial hypertension includes providing a patient a dry powder inhaler, providing the patient at least one capsule for use in the dry powder inhaler, the capsule including at least 25 micrograms of treprostinil.
Drugs covered by this patent
FDA Patent Use Codes
When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.
| Code | Description | Drug |
|---|---|---|
U-4200 |
— | treprostinil-sodium |
U-4200 |
— | treprostinil-sodium |
U-4200 |
— | treprostinil-sodium |
U-4200 |
— | treprostinil-sodium |
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.